BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1886 related articles for article (PubMed ID: 9506190)

  • 1. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin therapy in type 2 diabetes.
    Mudaliar S; Edelman SV
    Endocrinol Metab Clin North Am; 2001 Dec; 30(4):935-82. PubMed ID: 11727406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications.
    Porte D
    Diabetes Metab Res Rev; 2001; 17(3):181-8. PubMed ID: 11424231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
    Caballero AE
    J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
    Cosmi F; Cosmi D
    G Ital Cardiol (Rome); 2010 Jun; 11(6):460-6. PubMed ID: 20922871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic therapy for type 2 diabetes mellitus.
    DeFronzo RA
    Ann Intern Med; 1999 Aug; 131(4):281-303. PubMed ID: 10454950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
    Weinrauch LA; D'Elia JA; Finn P; Lewis EF; Desai AS; Claggett BL; Cooper ME; McGill JB
    Diabetes Res Clin Pract; 2016 Mar; 113():143-51. PubMed ID: 26830074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving glycaemic control with current therapies.
    Birkeland KI
    Diabet Med; 1998; 15 Suppl 4():S13-9. PubMed ID: 9868986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
    Diabetes; 1995 Nov; 44(11):1249-58. PubMed ID: 7589820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-insulin-dependent (type II) diabetes mellitus.
    Rodger W
    CMAJ; 1991 Dec; 145(12):1571-81. PubMed ID: 1742694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin.
    Chan JL; Abrahamson MJ
    Mayo Clin Proc; 2003 Apr; 78(4):459-67. PubMed ID: 12683698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.
    Standl E; Füchtenbusch M
    Diabetologia; 2003 Mar; 46 Suppl 1():M30-6. PubMed ID: 12652356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating hyperglycemia in type 2 diabetes: new goals and strategies.
    Lebovitz HE
    Cleve Clin J Med; 2002 Oct; 69(10):809-20. PubMed ID: 12371804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 95.